Trending Stock News

$-0.04 EPS Expected for Iteris, Inc. (ITI); Biolinerx Limited Ads (BLRX) SI Increased By 120.68%

Analysts expect Iteris, Inc. (NASDAQ:ITI) to report $-0.04 EPS on February, 8.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.04 EPS. After having $-0.03 EPS previously, Iteris, Inc.’s analysts see 33.33% EPS growth. The stock decreased 0.73% or $0.06 during the last trading session, reaching $7.47. About 364,257 shares traded or 77.27% up from the average. Iteris, Inc. (NASDAQ:ITI) has risen 136.03% since January 14, 2017 and is uptrending. It has outperformed by 119.33% the S&P500.

Biolinerx Limited Ads (NASDAQ:BLRX) had an increase of 120.68% in short interest. BLRX’s SI was 659,600 shares in January as released by FINRA. Its up 120.68% from 298,900 shares previously. With 709,700 avg volume, 1 days are for Biolinerx Limited Ads (NASDAQ:BLRX)’s short sellers to cover BLRX’s short positions. The SI to Biolinerx Limited Ads’s float is 1.14%. The stock decreased 3.33% or $0.04 during the last trading session, reaching $1.16. About 1.20 million shares traded or 107.46% up from the average. BioLine Rx Ltd (NASDAQ:BLRX) has declined 6.10% since January 14, 2017 and is downtrending. It has underperformed by 22.80% the S&P500.

Iteris, Inc. provides intelligent information solutions to traffic management and global agribusiness markets worldwide. The company has market cap of $244.92 million. It operates in three divisions: Roadway Sensors, Transportation Systems, and Agriculture and Weather Analytics. It currently has negative earnings. The Roadway Sensors segment provides vehicle detection and information systems and products for traffic intersection control, incident detection, and roadway traffic data collection applications.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company has market cap of $113.61 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. It currently has negative earnings. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx had 22 analyst reports since July 27, 2015 according to SRatingsIntel. Maxim Group upgraded the stock to “Buy” rating in Thursday, May 18 report. The firm earned “Buy” rating on Tuesday, November 21 by H.C. Wainwright. The stock of BioLine Rx Ltd (NASDAQ:BLRX) earned “Buy” rating by Oppenheimer on Monday, December 4. The stock of BioLine Rx Ltd (NASDAQ:BLRX) has “Buy” rating given on Thursday, August 3 by Roth Capital. H.C. Wainwright maintained the shares of BLRX in report on Friday, May 26 with “Buy” rating. H.C. Wainwright maintained BioLine Rx Ltd (NASDAQ:BLRX) rating on Wednesday, October 18. H.C. Wainwright has “Buy” rating and $4.0 target. The rating was maintained by H.C. Wainwright on Wednesday, August 9 with “Buy”. The stock has “Buy” rating by Maxim Group on Monday, July 10. The firm earned “Buy” rating on Monday, December 4 by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, December 21.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *